Published in Br J Cancer on October 24, 2006
Biology and management of pancreatic cancer. Gut (2007) 2.53
Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol (2009) 1.77
Targeting telomerase for cancer therapeutics. Br J Cancer (2008) 1.35
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Is telomerase a viable target in cancer? Mutat Res (2011) 1.23
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04
Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol (2011) 1.03
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother (2011) 0.99
Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol (2012) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med (2012) 0.96
Targeting telomerase-expressing cancer cells. J Cell Mol Med (2011) 0.96
Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol (2014) 0.95
Peptide Vaccine: Progress and Challenges. Vaccines (Basel) (2014) 0.94
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology (2012) 0.94
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91
Biological approaches to therapy of pancreatic cancer. Pancreatology (2008) 0.91
Vaccines for pancreatic cancer. Cancer J (2012) 0.90
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer (2016) 0.90
Risk factors and therapeutic targets in pancreatic cancer. Front Oncol (2013) 0.88
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist (2014) 0.87
New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84
What is recent in pancreatic cancer immunotherapy? Biomed Res Int (2012) 0.84
Vaccine therapy for pancreatic cancer. Oncoimmunology (2013) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie (2007) 0.83
Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines. Cell Mol Neurobiol (2010) 0.83
Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83
Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Surg Today (2015) 0.83
Gene therapy in pancreatic cancer. World J Gastroenterol (2014) 0.81
A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma. J Transl Med (2015) 0.79
Pancreatic cancer-improved care achievable. World J Gastroenterol (2014) 0.79
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res (2015) 0.78
Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) (2011) 0.78
Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol (2016) 0.77
Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol (2011) 0.77
Current advances in immunotherapy for pancreatic cancer. Curr Probl Cancer (2013) 0.77
Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer. Onco Targets Ther (2013) 0.77
A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol (2016) 0.77
Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner. Sci Rep (2016) 0.76
Therapeutic Targeting of Telomerase. Genes (Basel) (2016) 0.76
In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapy. J Thorac Dis (2013) 0.75
Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Immunol Res (2017) 0.75
Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother (2016) 0.75
Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol (2016) 0.75
The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget (2016) 0.75
Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer. Pharmgenomics Pers Med (2015) 0.75
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. Oncoimmunology (2016) 0.75
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol (2017) 0.75
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci (2017) 0.75
Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol (2017) 0.75
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.60
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer (1999) 2.03
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol (2005) 1.82
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A (2000) 1.26
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest (2004) 1.26
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother (2006) 1.23
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer (2001) 1.18
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol (2002) 1.06
Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res (2002) 1.05
Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood (2001) 1.05
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res (2004) 1.04
Is selection for TCR affinity a factor in cytokine polarization? Trends Immunol (2002) 1.03
Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res (2001) 1.02
Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene (1999) 1.02
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol (2001) 1.00
Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res (2003) 0.95
Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis. J Immunol (2001) 0.94
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A (2002) 0.92
Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol (1999) 0.91
Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am J Clin Pathol (1999) 0.90
Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer. Am J Gastroenterol (1998) 0.88
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood (2003) 0.87
Telomerase as a possible target for anticancer therapy. Chem Biol (1999) 0.86
Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res (1999) 0.82
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. Circulation (2000) 3.94
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Single-centre experience of laparoscopic pancreatic surgery. Br J Surg (2010) 2.31
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol (1996) 2.17
CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J Immunol (1990) 2.13
In vitro differentiation of human monocytes. Differences in monocyte phenotypes induced by cultivation on glass or on collagen. J Exp Med (1982) 2.02
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A (2001) 1.80
HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation--a fast and reliable technique. Tissue Antigens (1986) 1.67
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Laparoscopic resection of the pancreas: a feasibility study of the short-term outcome. Surg Endosc (2004) 1.59
Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer (1997) 1.57
Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules. J Cell Biol (1995) 1.57
Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res (1999) 1.56
PACAP and glutamate are co-stored in the retinohypothalamic tract. J Comp Neurol (2000) 1.49
Outpatient laparoscopic cholecystectomy. Br J Surg (1997) 1.45
Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes (1996) 1.44
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
High-throughput biological small-angle X-ray scattering with a robotically loaded capillary cell. J Appl Crystallogr (2012) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells. Leukemia (1992) 1.39
Isolation of pure functionally active CD8+ T cells. Positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres. J Immunol Methods (1986) 1.38
T cells recognize a peptide derived from alpha-gliadin presented by the celiac disease-associated HLA-DQ (alpha 1*0501, beta 1*0201) heterodimer. Hum Immunol (1994) 1.37
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Fractal analysis and time- and frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failure. Am J Cardiol (2001) 1.33
Induction of various HLA class II molecules in a human colonic adenocarcinoma cell line. Scand J Immunol (1987) 1.33
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer (1994) 1.31
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 1.29
Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Semin Cancer Biol (1999) 1.27
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Rupture of fetal membranes and premature delivery associated with group B streptococci in urine of pregnant women. Lancet (1984) 1.26
Immunocytochemical demonstration of retinal S-antigen in the pineal organ of four mammalian species. Cell Tissue Res (1985) 1.26
Direct immunomagnetic quantification of lymphocyte subsets in blood. Clin Exp Immunol (1988) 1.24
Changing molecular epidemiology of methicillin-resistant Staphylococcus aureus in a small geographic area over an eight-year period. J Clin Microbiol (2007) 1.24
Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol (1998) 1.23
Identification of a putative motif for binding of peptides to HLA-DQ2. Int Immunol (1996) 1.22
Depletion of T lymphocytes from human bone marrow. Use of magnetic monosized polymer microspheres coated with T-lymphocyte-specific monoclonal antibodies. Transplantation (1987) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Immunohistochemical demonstration of S-100 protein and GFA protein in interstitial cells of rat pineal gland. Brain Res (1978) 1.19
Cholecystectomy rates, gallstone prevalence, and handling of bile duct injuries in Scandinavia. A comparative audit. Surg Endosc (1998) 1.19
Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 1.18
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer (2001) 1.18
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 1.17
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Dendritic cells and monocytes as accessory cells in T-cell responses in man. I. Phenotypic analysis of dendritic cells and monocytes. Scand J Immunol (1985) 1.13
Long-term effect of pelvic floor exercises on female urinary incontinence. Br J Urol (1991) 1.10
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther (2006) 1.08
The effect of sterile water blocks on low back labor pain. Am J Obstet Gynecol (1991) 1.07
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
Vesicular transport of cationized ferritin by the epithelium of the rat choroid plexus. J Cell Biol (1981) 1.06
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience (2003) 1.04
Bile duct injury in laparoscopic cholecystectomy. Int Surg (1996) 1.04
Plasma catecholamines and haemodynamic changes during pneumoperitoneum. Acta Anaesthesiol Scand (1998) 1.03
Uptake of horseradish peroxidase from CSF into the choroid plexus of the rat, with special reference to transepithelial transport. Cell Tissue Res (1978) 1.03
Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Adv Cancer Res (1999) 1.02
Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4+ T cells. J Virol Methods (1989) 1.01
Improving the efficacy of cancer immunotherapy. Eur J Cancer (2009) 1.01
A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother (2001) 1.00
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer (2005) 1.00
Search for supersymmetry in events with three leptons and missing transverse momentum in √[s]=7 TeV pp collisions with the ATLAS detector. Phys Rev Lett (2012) 0.99
Topographical organization of the rat suprachiasmatic-paraventricular projection. J Comp Neurol (1995) 0.99
Localization of receptors and early events of phagocytosis in the macrophage. Exp Cell Res (1975) 0.99
Mutagenicity of polycyclic aromatic compounds (PAC) identified in source emissions and ambient air. Mutat Res (1985) 0.99
Mutagenicity in emissions from coal- and oil-fired boilers. Environ Health Perspect (1983) 0.99
CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother (1995) 0.98
Day-case laparoscopic fundoplication for gastro-oesophageal reflux disease. Br J Surg (2000) 0.97
Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol (1982) 0.97
Monoaminergic systems in the brainstem and spinal cord of the turtle Pseudemys scripta elegans as revealed by antibodies against serotonin and tyrosine hydroxylase. J Comp Neurol (1992) 0.96
HLA-DQw3.1 and DQw3.2 associated exon polymorphisms detected by oligonucleotide probes. Tissue Antigens (1988) 0.96
Outpatient laparoscopic surgery: feasibility and consequences for education and health care costs. Surg Endosc (2004) 0.96
Lacrimal gland electrolyte and water secretion in the rabbit: localization and role of (Na+ + K+)-activated ATPase. J Physiol (1981) 0.95
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer (1996) 0.95
K-ras mutations and HLA-DR expression in large bowel adenomas. Br J Cancer (1996) 0.94
Global gene expression analysis in fetal mouse ovaries with and without meiosis and comparison of selected genes with meiosis in the testis. Cell Tissue Res (2006) 0.94
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur J Immunol (1993) 0.94
Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol (2013) 0.94
The time course of serotonin 2C receptor expression after spinal transection of rats: an immunohistochemical study. Neuroscience (2013) 0.94
Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. Am J Cardiol (1993) 0.94
Metacarpal morphometry in monozygotic dizygotic elderly twins. Calcif Tissue Res (1978) 0.94
Smoking, sex of the offspring, and risk of placental abruption, placenta previa, and preeclampsia: a population-based cohort study. Acta Obstet Gynecol Scand (2001) 0.94
A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol (2003) 0.93
K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol (1997) 0.93
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur J Immunol (1994) 0.93
Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur J Radiol (2001) 0.92
Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations. Biotechniques (2001) 0.92
Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue, and peripheral blood of patients with inflammatory arthritides. Scand J Immunol (1989) 0.92
In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha 2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-alpha. J Acquir Immune Defic Syndr (1991) 0.92